Pharmaxis (phase 1 NASH PXS4728A, asset) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Pharmaxis (phase 1 NASH PXS4728A, asset) General Information

Description

An investigational drug used for the treatment of liver-related diseases. The investigational drug helps in blocking leukocyte adhesion and tissue infiltration in inflammatory processes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Locked Bag 5015
  • Frenchs Forest, Australian Capital Territory 2086
  • Australia
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Boehringer Ingelheim
Corporate Office
  • Locked Bag 5015
  • Frenchs Forest, Australian Capital Territory 2086
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharmaxis (phase 1 NASH PXS4728A, asset) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharmaxis (phase 1 NASH PXS4728A, asset)‘s full profile, request access.

Request a free trial

Pharmaxis (phase 1 NASH PXS4728A, asset) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharmaxis (phase 1 NASH PXS4728A, asset)‘s full profile, request access.

Request a free trial

Pharmaxis (phase 1 NASH PXS4728A, asset) FAQs

  • Where is Pharmaxis (phase 1 NASH PXS4728A, asset) headquartered?

    Pharmaxis (phase 1 NASH PXS4728A, asset) is headquartered in Frenchs Forest, Australia.

  • What industry is Pharmaxis (phase 1 NASH PXS4728A, asset) in?

    Pharmaxis (phase 1 NASH PXS4728A, asset)’s primary industry is Buildings and Property.

  • Is Pharmaxis (phase 1 NASH PXS4728A, asset) a private or public company?

    Pharmaxis (phase 1 NASH PXS4728A, asset) is a Private company.

  • What is the current valuation of Pharmaxis (phase 1 NASH PXS4728A, asset)?

    The current valuation of Pharmaxis (phase 1 NASH PXS4728A, asset) is .

  • What is Pharmaxis (phase 1 NASH PXS4728A, asset)’s current revenue?

    The current revenue for Pharmaxis (phase 1 NASH PXS4728A, asset) is .

  • Who are Pharmaxis (phase 1 NASH PXS4728A, asset)’s investors?

    Orbis Investment Management, Syntara, and Talu Ventures have invested in Pharmaxis (phase 1 NASH PXS4728A, asset).

  • When was Pharmaxis (phase 1 NASH PXS4728A, asset) acquired?

    Pharmaxis (phase 1 NASH PXS4728A, asset) was acquired on 18-May-2015.

  • Who acquired Pharmaxis (phase 1 NASH PXS4728A, asset)?

    Pharmaxis (phase 1 NASH PXS4728A, asset) was acquired by Boehringer Ingelheim.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process